NervGen Pharma Announces Results of Annual General Meeting of Shareholders
All resolutions submitted for approval were passed by shareholders Glenn Ives appointed as Chair of the Board John Ruffolo appointed as Chair of the Audit Committee Vancouver, Canada, June 5, 2024 — NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, […]
NervGen Pharma to Present Two Posters at the American Spinal Injury Association 51st Annual Scientific Meeting
Vancouver, Canada, May 17, 2024 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Daniel Mikol, MD, Ph.D., Chief Medical Officer, will be presenting two posters at the upcoming American Spinal Injury Association (ASIA) 51st Annual Scientific […]
NervGen Pharma Reports Q1 2024 Financial Results and Operational Updates
Target for completing enrollment of the chronic cohort in the Phase 1b/2a clinical trial moved to Q3 2024 Subacute cohort protocol being amended to enhance feasibility and lessen burden on participants CA$23 million bought deal financing completed in March 2024 provides expected cash runway through Q3 2025 Vancouver, Canada, May 16, 2024 – NervGen […]
NervGen Files Management Information Circular and Announces Board of Directors Transition
Bill Radvak to transition to Board Advisor following decision to not stand for re-election to NervGen’s Board of Directors Annual General Meeting of Shareholders to be held on June 4, 2024 Vancouver, Canada, May 7, 2024 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical-stage biotech company dedicated to […]
NervGen Engages Russo Partners LLC to Provide Public Relations Services
Vancouver, Canada, April 25, 2024 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that it has engaged Russo Partners LLC (“Russo Partners”), a New York based full-service strategic communications firm to provide media […]
NervGen Pharma Reports 2023 Year-End Financial Results and Operational Updates
Anticipated completion of enrollment of the chronic cohort in the Phase 1b/2a clinical trial in Q2 2024 CA$23 million bought deal financing completed in March 2024 provides expected cash runway through Q3 2025 Fast Track designation granted by U.S. Food and Drug Administration (FDA) for NVG-291 in spinal cord injury Vancouver, Canada April 17, […]
NervGen Completes $23 Million Bought Deal Financing
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. Vancouver, British Columbia March 28, 2024 – NervGen Pharma Corp. (“NervGen” or the “Company”) (TSXV: NGEN) is pleased to announce the closing of its previously announced public offering (the “Offering”) including the full exercise of the underwriters’ over-allotment […]
NervGen Announces $20 Million Bought Deal Offering
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. Vancouver, British Columbia March 21, 2024 – NervGen Pharma Corp. (“NervGen” or the “Company”) (TSXV: NGEN) is pleased to announce that it has entered into an agreement with a syndicate of underwriters led by Stifel Canada, Canaccord Genuity […]
NervGen Pharma Recognized as a Top 50 TSX Venture Exchange Company
Vancouver, Canada, February 21, 2024 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, has been recognized by the TSX Venture Exchange as a 2023 Top 50 Company. The 2024 TSX Venture 50™ showcases the strongest performances on the TSX […]
NervGen Pharma Grants Stock Options
Vancouver, Canada, February 20, 2024 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced that it has granted incentive stock options to the Company’s employees, including 505,200 to the Company’s Officers exercisable at a price of $3.48 per […]